Switch to:
Also traded in: Argentina, Austria, Belgium, Brazil, Chile, Germany, Mexico, Sweden, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.36
PFE's Cash-to-Debt is ranked lower than
77% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. PFE: 0.36 )
Ranked among companies with meaningful Cash-to-Debt only.
PFE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.63 Max: 3.47
Current: 0.36
0.14
3.47
Equity-to-Asset 0.43
PFE's Equity-to-Asset is ranked lower than
77% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. PFE: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
PFE' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.46 Max: 0.66
Current: 0.43
0.35
0.66
Debt-to-Equity 0.68
PFE's Debt-to-Equity is ranked lower than
68% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. PFE: 0.68 )
Ranked among companies with meaningful Debt-to-Equity only.
PFE' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1  Med: 0.47 Max: 0.79
Current: 0.68
0.1
0.79
Debt-to-EBITDA 2.27
PFE's Debt-to-EBITDA is ranked lower than
52% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. PFE: 2.27 )
Ranked among companies with meaningful Debt-to-EBITDA only.
PFE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.13  Med: 2.05 Max: 2.89
Current: 2.27
1.13
2.89
Interest Coverage 11.19
PFE's Interest Coverage is ranked lower than
69% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. PFE: 11.19 )
Ranked among companies with meaningful Interest Coverage only.
PFE' s Interest Coverage Range Over the Past 10 Years
Min: 7.87  Med: 11.17 Max: 22.47
Current: 11.19
7.87
22.47
Piotroski F-Score: 7
Altman Z-Score: 3.05
Beneish M-Score: -2.34
WACC vs ROIC
6.90%
25.57%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 26.76
PFE's Operating Margin % is ranked higher than
90% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. PFE: 26.76 )
Ranked among companies with meaningful Operating Margin % only.
PFE' s Operating Margin % Range Over the Past 10 Years
Min: 20.88  Med: 26.91 Max: 31.73
Current: 26.76
20.88
31.73
Net Margin % 44.63
PFE's Net Margin % is ranked higher than
97% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. PFE: 44.63 )
Ranked among companies with meaningful Net Margin % only.
PFE' s Net Margin % Range Over the Past 10 Years
Min: 12.18  Med: 17.03 Max: 42.65
Current: 44.63
12.18
42.65
ROE % 34.69
PFE's ROE % is ranked higher than
95% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. PFE: 34.69 )
Ranked among companies with meaningful ROE % only.
PFE' s ROE % Range Over the Past 10 Years
Min: 9.29  Med: 12.08 Max: 32.57
Current: 34.69
9.29
32.57
ROA % 14.16
PFE's ROA % is ranked higher than
87% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. PFE: 14.16 )
Ranked among companies with meaningful ROA % only.
PFE' s ROA % Range Over the Past 10 Years
Min: 4.05  Med: 5.36 Max: 12.41
Current: 14.16
4.05
12.41
ROC (Joel Greenblatt) % 95.95
PFE's ROC (Joel Greenblatt) % is ranked higher than
96% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. PFE: 95.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PFE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 41.83  Med: 67.27 Max: 99.88
Current: 95.95
41.83
99.88
3-Year Revenue Growth Rate 4.00
PFE's 3-Year Revenue Growth Rate is ranked lower than
55% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. PFE: 4.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PFE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.8  Med: 6.4 Max: 19.2
Current: 4
-3.8
19.2
3-Year EBITDA Growth Rate 3.20
PFE's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. PFE: 3.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
PFE' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.1  Med: 9.6 Max: 38.4
Current: 3.2
-10.1
38.4
3-Year EPS without NRI Growth Rate 35.70
PFE's 3-Year EPS without NRI Growth Rate is ranked higher than
82% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. PFE: 35.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PFE' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.8  Med: 7.4 Max: 90.5
Current: 35.7
-26.8
90.5
GuruFocus has detected 7 Warning Signs with Pfizer Inc PFE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PFE's 30-Y Financials

Financials (Next Earnings Date: 2019-01-31 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

PFE Guru Trades in Q4 2017

Tom Russo 1,900 sh (New)
Steven Cohen 351,897 sh (New)
Paul Tudor Jones 25,136 sh (New)
First Pacific Advisors 13,000 sh (New)
Ken Fisher 36,372,349 sh (+3.56%)
First Eagle Investment 79,061 sh (+19.68%)
Joel Greenblatt 49,922 sh (+128.82%)
Richard Pzena 4,361,143 sh (+8.80%)
John Buckingham 87,558 sh (+3.46%)
Pioneer Investments 19,093,990 sh (+81.32%)
Ronald Muhlenkamp 27,494 sh (unchged)
Robert Bruce 455,332 sh (unchged)
Murray Stahl 74,956 sh (unchged)
Prem Watsa 210,000 sh (unchged)
David Carlson 650,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,327,953 sh (unchged)
Lee Ainslie Sold Out
David Dreman 14,424 sh (-50.62%)
T Rowe Price Equity Income Fund 8,520,000 sh (-10.93%)
Dodge & Cox 477,331 sh (-9.88%)
Charles Brandes 3,707,279 sh (-2.99%)
Kahn Brothers 554,606 sh (-0.52%)
NWQ Managers 1,072,487 sh (-1.71%)
Jeremy Grantham 4,019,297 sh (-2.93%)
Jeff Auxier 78,618 sh (-3.02%)
Jim Simons 996,641 sh (-82.23%)
Mairs and Power 4,717,328 sh (-1.04%)
Diamond Hill Capital 10,909,103 sh (-1.97%)
Barrow, Hanley, Mewhinney & Strauss 42,212,028 sh (-5.01%)
Mario Gabelli 386,031 sh (-19.09%)
Smead Capital Management, Inc. 1,821,728 sh (-4.37%)
» More
Q1 2018

PFE Guru Trades in Q1 2018

Richard Snow 5,752 sh (New)
Ray Dalio 194,322 sh (New)
Ken Fisher 37,773,806 sh (+3.85%)
Joel Greenblatt 1,414,110 sh (+2732.64%)
Robert Bruce 555,332 sh (+21.96%)
Richard Pzena 4,367,493 sh (+0.15%)
John Buckingham 91,035 sh (+3.97%)
Jeremy Grantham 4,282,113 sh (+6.54%)
Mario Gabelli 387,501 sh (+0.38%)
David Dreman 14,424 sh (unchged)
David Carlson 650,000 sh (unchged)
First Eagle Investment Sold Out
Tom Russo Sold Out
Prem Watsa Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons Sold Out
First Pacific Advisors Sold Out
Ronald Muhlenkamp 27,239 sh (-0.93%)
T Rowe Price Equity Income Fund 8,290,000 sh (-2.70%)
Dodge & Cox 442,209 sh (-7.36%)
Charles Brandes 3,501,649 sh (-5.55%)
Kahn Brothers 549,944 sh (-0.84%)
Murray Stahl 73,367 sh (-2.12%)
NWQ Managers 1,035,107 sh (-3.49%)
Jeff Auxier 78,280 sh (-0.43%)
Mairs and Power 4,227,070 sh (-10.39%)
Diamond Hill Capital 9,507,569 sh (-12.85%)
Barrow, Hanley, Mewhinney & Strauss 41,155,163 sh (-2.50%)
Pioneer Investments 15,324,323 sh (-19.74%)
Eaton Vance Worldwide Health Sciences Fund 1,135,385 sh (-14.50%)
Smead Capital Management, Inc. 1,818,721 sh (-0.17%)
» More
Q2 2018

PFE Guru Trades in Q2 2018

Paul Tudor Jones 28,230 sh (New)
Caxton Associates 10,108 sh (New)
Ken Fisher 39,445,117 sh (+4.42%)
Ronald Muhlenkamp 27,485 sh (+0.90%)
Richard Pzena 4,456,667 sh (+2.04%)
John Buckingham 91,759 sh (+0.80%)
David Carlson 750,000 sh (+15.38%)
Pioneer Investments 15,803,261 sh (+3.13%)
Ray Dalio 386,306 sh (+98.80%)
Robert Bruce 555,332 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,135,385 sh (unchged)
Richard Snow Sold Out
T Rowe Price Equity Income Fund 8,210,000 sh (-0.97%)
Dodge & Cox 434,124 sh (-1.83%)
Joel Greenblatt 1,273,299 sh (-9.96%)
Charles Brandes 3,423,062 sh (-2.24%)
Kahn Brothers 546,967 sh (-0.54%)
Murray Stahl 70,013 sh (-4.57%)
NWQ Managers 679,136 sh (-34.39%)
Jeremy Grantham 2,987,204 sh (-30.24%)
Mairs and Power 3,971,728 sh (-6.04%)
Diamond Hill Capital 8,556,036 sh (-10.01%)
Barrow, Hanley, Mewhinney & Strauss 39,241,645 sh (-4.65%)
Mario Gabelli 342,380 sh (-11.64%)
Smead Capital Management, Inc. 1,786,423 sh (-1.78%)
Jeff Auxier 76,180 sh (-2.68%)
» More
Q3 2018

PFE Guru Trades in Q3 2018

Lee Ainslie 204,950 sh (New)
Ken Fisher 40,477,731 sh (+2.62%)
Pioneer Investments 17,247,572 sh (+9.14%)
T Rowe Price Equity Income Fund 8,210,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 1,135,385 sh (unchged)
David Carlson 750,000 sh (unchged)
Robert Bruce 555,332 sh (unchged)
NWQ Managers Sold Out
Caxton Associates Sold Out
Paul Tudor Jones Sold Out
Smead Capital Management, Inc. 1,741,315 sh (-2.53%)
Kahn Brothers 537,309 sh (-1.77%)
Mario Gabelli 320,811 sh (-6.30%)
Charles Brandes 3,340,003 sh (-2.43%)
Richard Pzena 4,438,430 sh (-0.41%)
Barrow, Hanley, Mewhinney & Strauss 35,037,671 sh (-10.71%)
Diamond Hill Capital 8,048,995 sh (-5.93%)
Ronald Muhlenkamp 26,430 sh (-3.84%)
Ray Dalio 298,598 sh (-22.70%)
Jeremy Grantham 1,030,132 sh (-65.52%)
Mairs and Power 3,473,458 sh (-12.55%)
Murray Stahl 65,963 sh (-5.78%)
Joel Greenblatt 453,641 sh (-64.37%)
John Buckingham 91,402 sh (-0.39%)
Jeff Auxier 75,880 sh (-0.39%)
Dodge & Cox 433,024 sh (-0.25%)
» More
» Details

Insider Trades

Latest Guru Trades with PFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XSWX:ROG, XSWX:NOVN, NYSE:MRK, NYSE:ABBV, XTER:BAYN, LSE:GSK, XPAR:SAN, NYSE:JNJ, NYSE:LLY, LSE:AZN, NYSE:BMY, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, TSE:4151, TSE:4528, SHSE:600436, SHSE:600867 » details
Traded in other countries:PFE.Argentina, PFE.Austria, PFEBC.Belgium, PFIZ34.Brazil, PFE.Chile, PFE.Germany, PFE.Mexico, PFE.Sweden, PFE.Switzerland, 0Q1N.UK,
Headquarter Location:USA
Pfizer Inc is a biopharmaceutical company that discovers, develops, manufactures, and markets healthcare products including medicines, and vaccines as well as many of the consumer healthcare products.

Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Prescription drugs and vaccines account for the majority of sales. Top sellers include vaccine Prevnar 13 against meningitis and Lyrica for epilepsy and some types of neuropathic pain. Pfizer sells these products globally with international sales representing close to 50% of its total sales.

Top Ranked Articles about Pfizer Inc

Phil Fisher: When to Buy Stocks Using corporate conditions to time entry into stock purchases
In previous chapters of “Common Stocks and Uncommon Profits and Other Writings,” Philip Fisher argued that investing successfully means finding stocks that are expected to post strong earnings per share growth in coming years. Read more...
Report: Exploring Fundamental Drivers Behind Pfizer, eBay, ABM Industries, Quad Graphics, FireEye, and BJ's Restaurants — New Horizons, Emerging Trends, and Upcoming Developments
Astellas Receives Positive CHMP Opinion for XTANDI® (enzalutamide) for Adult Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Brandes Investments Expands Stake in Avadel Pharmaceuticals Firm that seeks mispricings buys as share fall
The firm founded Charles Brandes (Trades, Portfolio), Brandes Investment Partners, on Thursday announced that it expanded its position in Avadel Pharmaceuticals Plc (NASDAQ:AVDL) to 13.5% of the company, enlarging its exposure to health care, the second-largest sector represented in its portfolio. Read more...
Tweedy Browne's Dumping Spree in 2nd Quarter The firm tossed the stock of this tobacco giant after holding over five years for an estimated return of 24%. Only one new buy in the second quarter
Tweedy Browne (Trades, Portfolio) Co. was busier dumping and reducing stakes than establishing new ones in the second quarter of the year, filings showed. Read more...
Pfizer Rises on Earnings Beat Company lowers annual revenue guidance
Pharmaceutical giant Pfizer Inc. (NYSE:PFE) reported strong second-quarter earnings before the opening bell on Tuesday, but disappointed shareholders with a lower revenue forecast for the year. Read more...
Pfizer's New Report Shows How Behavioural Science Can Help Boost Preventative Healthcare Measures
Regulator Approves Pfizer Drug for US Patients The drug will be used in the US for treatment of anemia
Pfizer Inc. (NYSE:PFE) has informed the market that it received the U.S. Food and Drug Administration’s approval for a drug it has developed to treat anemia resulting from chemotherapy or chronic kidney disease. Read more...
BioDuro Collaboration with Pfizer Inc. Leads to Creation of a Shelf-Stable Fluorosulfation Reagent
Neofluidics Announces Collaboration with Pfizer Inc.

Ratios

vs
industry
vs
history
PE Ratio 11.06
PFE's PE Ratio is ranked higher than
90% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. PFE: 11.06 )
Ranked among companies with meaningful PE Ratio only.
PFE' s PE Ratio Range Over the Past 10 Years
Min: 7.68  Med: 17.01 Max: 34.43
Current: 11.06
7.68
34.43
Forward PE Ratio 14.25
PFE's Forward PE Ratio is ranked higher than
79% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. PFE: 14.25 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 11.06
PFE's PE Ratio without NRI is ranked higher than
90% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. PFE: 11.06 )
Ranked among companies with meaningful PE Ratio without NRI only.
PFE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.58  Med: 19.36 Max: 34.43
Current: 11.06
9.58
34.43
Price-to-Owner-Earnings 9.53
PFE's Price-to-Owner-Earnings is ranked higher than
91% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. PFE: 9.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
PFE' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.44  Med: 10.65 Max: 30.72
Current: 9.53
5.44
30.72
PB Ratio 3.60
PFE's PB Ratio is ranked lower than
61% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. PFE: 3.60 )
Ranked among companies with meaningful PB Ratio only.
PFE' s PB Ratio Range Over the Past 10 Years
Min: 1.32  Med: 2.4 Max: 3.8
Current: 3.6
1.32
3.8
PS Ratio 4.93
PFE's PS Ratio is ranked lower than
64% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. PFE: 4.93 )
Ranked among companies with meaningful PS Ratio only.
PFE' s PS Ratio Range Over the Past 10 Years
Min: 1.72  Med: 3.73 Max: 5.21
Current: 4.93
1.72
5.21
Price-to-Free-Cash-Flow 16.81
PFE's Price-to-Free-Cash-Flow is ranked higher than
77% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. PFE: 16.81 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
PFE' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.02  Med: 13.73 Max: 18.91
Current: 16.81
5.02
18.91
Price-to-Operating-Cash-Flow 14.76
PFE's Price-to-Operating-Cash-Flow is ranked higher than
72% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. PFE: 14.76 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
PFE' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.55  Med: 12.21 Max: 15.89
Current: 14.76
4.55
15.89
EV-to-EBIT 18.91
PFE's EV-to-EBIT is ranked lower than
53% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. PFE: 18.91 )
Ranked among companies with meaningful EV-to-EBIT only.
PFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.9  Med: 14.45 Max: 28.9
Current: 18.91
6.9
28.9
EV-to-EBITDA 13.32
PFE's EV-to-EBITDA is ranked higher than
62% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. PFE: 13.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
PFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 9.4 Max: 17.3
Current: 13.32
5
17.3
EV-to-Revenue 5.33
PFE's EV-to-Revenue is ranked lower than
64% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. PFE: 5.33 )
Ranked among companies with meaningful EV-to-Revenue only.
PFE' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.8 Max: 5.8
Current: 5.33
1.6
5.8
Shiller PE Ratio 22.84
PFE's Shiller PE Ratio is ranked higher than
73% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. PFE: 22.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
PFE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.05  Med: 16.72 Max: 24.08
Current: 22.84
9.05
24.08
Current Ratio 1.43
PFE's Current Ratio is ranked lower than
82% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. PFE: 1.43 )
Ranked among companies with meaningful Current Ratio only.
PFE' s Current Ratio Range Over the Past 10 Years
Min: 0.98  Med: 1.49 Max: 3.18
Current: 1.43
0.98
3.18
Quick Ratio 1.15
PFE's Quick Ratio is ranked lower than
78% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. PFE: 1.15 )
Ranked among companies with meaningful Quick Ratio only.
PFE' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.21 Max: 2.86
Current: 1.15
0.74
2.86
Days Inventory 254.64
PFE's Days Inventory is ranked lower than
88% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. PFE: 254.64 )
Ranked among companies with meaningful Days Inventory only.
PFE' s Days Inventory Range Over the Past 10 Years
Min: 195.67  Med: 233.12 Max: 344.63
Current: 254.64
195.67
344.63
Days Sales Outstanding 68.55
PFE's Days Sales Outstanding is ranked higher than
62% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. PFE: 68.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
PFE' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.83  Med: 66.96 Max: 106.89
Current: 68.55
56.83
106.89
Days Payable 137.09
PFE's Days Payable is ranked higher than
73% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. PFE: 137.09 )
Ranked among companies with meaningful Days Payable only.
PFE' s Days Payable Range Over the Past 10 Years
Min: 78.79  Med: 122.74 Max: 179.46
Current: 137.09
78.79
179.46

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.11
PFE's Dividend Yield % is ranked higher than
87% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. PFE: 3.11 )
Ranked among companies with meaningful Dividend Yield % only.
PFE' s Dividend Yield % Range Over the Past 10 Years
Min: 2.9  Med: 3.63 Max: 10.4
Current: 3.11
2.9
10.4
Dividend Payout Ratio 0.34
PFE's Dividend Payout Ratio is ranked higher than
56% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. PFE: 0.34 )
Ranked among companies with meaningful Dividend Payout Ratio only.
PFE' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.34  Med: 0.74 Max: 1.08
Current: 0.34
0.34
1.08
3-Year Dividend Growth Rate 7.20
PFE's 3-Year Dividend Growth Rate is ranked higher than
50% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. PFE: 7.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
PFE' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -14.7  Med: 12.6 Max: 22.6
Current: 7.2
-14.7
22.6
Forward Dividend Yield % 3.29
PFE's Forward Dividend Yield % is ranked higher than
88% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. PFE: 3.29 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.50
PFE's 5-Year Yield-on-Cost % is ranked higher than
92% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. PFE: 4.50 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PFE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 4.22  Med: 5.28 Max: 15.14
Current: 4.5
4.22
15.14
3-Year Average Share Buyback Ratio 1.70
PFE's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. PFE: 1.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PFE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -17.6  Med: 0.2 Max: 7.2
Current: 1.7
-17.6
7.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.34
PFE's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. PFE: 1.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
PFE' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.16 Max: 9.98
Current: 1.34
0.53
9.98
Price-to-Median-PS-Value 1.32
PFE's Price-to-Median-PS-Value is ranked lower than
70% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. PFE: 1.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PFE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.05 Max: 3.19
Current: 1.32
0.47
3.19
Earnings Yield (Greenblatt) % 5.29
PFE's Earnings Yield (Greenblatt) % is ranked higher than
65% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. PFE: 5.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PFE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.5  Med: 6.9 Max: 14.5
Current: 5.29
3.5
14.5
Forward Rate of Return (Yacktman) % 5.18
PFE's Forward Rate of Return (Yacktman) % is ranked lower than
62% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. PFE: 5.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
PFE' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.9  Med: 10.2 Max: 15
Current: 5.18
1.9
15

More Statistics

Revenue (TTM) (Mil) $53,373.00
EPS (TTM) $ 3.96
Beta0.75
Volatility14.30%
52-Week Range $33.20 - 46.47
Shares Outstanding (Mil)5,780.47

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 53,628 55,015 55,408
EBIT (Mil $) 19,431 20,495 21,556
EBITDA (Mil $) 23,354 24,369 24,650
EPS ($) 2.33 2.41 2.66
EPS without NRI ($) 2.33 2.41 2.66
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.05%
Dividends per Share ($) 1.39 1.45 1.52

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}